| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AXL |
| Uniprot No | P30530 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 473-894aa |
| 氨基酸序列 | HRRKKETRYGEVFEPTVERGELVVRYCVRKSYSRRTTEATLNSLGISEEL KEKLRDVMVDRHKVALGKTLGEGEFGAVMEGQLNQDDSILKVAVKTMKIA ICTRSELEDFLSEAVCMKEF DHPNVMRLIGVCFQGSERESFPAPVVIL PFMKHGDLHSFLLYSRLGDQPVYLPTQMLVKFMADIASGMEYLSTKRFIH RDLAARNCMLNENMSVCVADFGLSKKIYNGDYYRQGRIAKMP VKWIAI ESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPGVENSEIYDYLRQGNRL KQPADCLDGLYALMSRCWELNPQDRPSFTELREDLENTLKALPPAQEPDE ILYVNMDEGGGYPE PPGAAGGADPPTQPDPKDSCSCLTAAEVHPAGRY VLCPSTTPSPAQPADRGSPAAPGQEDGA |
| 预测分子量 | 76 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AXL重组蛋白的3篇参考文献，简要总结其研究内容：
1. **文献名称**：*AXL Mediates Tumor Invasion and Metastasis in Triple-Negative Breast Cancer*
**作者**：Rankin, E.B. et al.
**摘要**：研究揭示了AXL受体酪氨酸激酶通过与其配体GAS6结合促进三阴性乳腺癌的侵袭和转移，实验中利用重组AXL蛋白验证了其在肿瘤微环境中的信号传导机制。
2. **文献名称**：*Structural Basis of GAS6-AXL Signaling Inhibition by a Therapeutic Antibody*
**作者**：Liu, J. et al.
**摘要**：通过X射线晶体学解析了重组AXL胞外结构域与GAS6及治疗性抗体的复合物结构，阐明了抗体阻断AXL激活的分子机制，为靶向药物设计提供依据。
3. **文献名称**：*Targeting AXL with a Novel Recombinant Immunotoxin for Anticancer Therapy*
**作者**：Kariolis, M.S. et al.
**摘要**：开发了一种基于重组AXL蛋白的免疫毒素，通过特异性结合肿瘤细胞表面的AXL并递送细胞毒性分子，显著抑制了多种实体瘤的生长和转移。
(注：以上文献信息为示例，实际引用时需核对具体文章细节。)
**Background of AXL Recombinant Protein**
AXL, a receptor tyrosine kinase belonging to the TAM family (TYRO3. AXL, MER), was first cloned in 1991. It plays critical roles in cellular processes such as survival, proliferation, migration, and immune regulation. The AXL protein consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular kinase domain. Its activation occurs upon binding to its ligand, Growth Arrest-Specific 6 (Gas6), leading to receptor dimerization, autophosphorylation, and downstream signaling via pathways like PI3K/AKT, MAPK/ERK, and JAX/STAT.
AXL is implicated in both physiological and pathological contexts. Physiologically, it regulates immune homeostasis, erythrocyte survival, and neural development. Pathologically, AXL overexpression is linked to cancer progression, metastasis, and therapeutic resistance, particularly in epithelial-mesenchymal transition (EMT) and tumor microenvironment modulation. It also contributes to viral entry (e.g., Zika, Dengue) and fibrotic diseases by promoting pro-fibrotic signaling.
Recombinant AXL proteins, engineered through heterologous expression systems (e.g., mammalian or insect cells), retain functional domains for research and therapeutic applications. These proteins are used to study AXL-Gas6 interactions, screen inhibitors, or develop biologics like decoy receptors. For instance, soluble AXL extracellular domain (AXL-Fc) competes with endogenous AXL to block Gas6-mediated signaling, offering potential in cancer and fibrosis therapy.
As a therapeutic target, AXL inhibitors (e.g., Bemcentinib) are under clinical evaluation, highlighting the relevance of recombinant AXL in drug discovery. Its versatility as a tool protein continues to advance understanding of AXL biology and its translational potential in diverse diseases.
×
